Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 41 Issue 10, October 2023

Inhalable delivery vehicles

Inhalation of RNA-lipid nanoparticles: Li et al. developed lipid nanoparticles for the pulmonary delivery of RNA-based gene editors, paving the way for treating inherited lung diseases through direct inhalation of gene therapies.

See Li et al.

Image: Bowen Li, University of Toronto. Cover Design: Erin Dewalt

Editorial

  • Decentralized autonomous organizations are growing as alternative research funding models, but are also strong scientific communities. We should get on board.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Features

Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

Top of page ⤴

Research Briefings

  • The ability to create in vivo genomic medicines for tissues other than the liver has been impeded by difficulties in delivery. Using a high-throughput platform, we developed lipid nanoparticles that can effectively deliver mRNA and CRISPR–Cas9 gene editing tools to the lungs through intratracheal administration, expanding the potential clinical uses of gene editing and mRNA-based technologies.

    Research Briefing
Top of page ⤴

Research

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Careers & Recruitment

  • Career Feature

  • People

    • Recent moves of note in and around the biotech and pharma industries.

      People
Top of page ⤴

Search

Quick links